1 Chen, Z., Chen, G.Q., Shen, Z.X., Chen, S.J., Wang, Z.Y., “Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies”, Seminars in Hematology, 38(1), 26—36(2001). 2 Evens, A.M., Tallman, M.S., Gartenhaus, R.B., “The po-tential of arsenic trioxide in the treatment of malignant disease: Past, present, and future”, Leukemia Research, 28(9), 891—900(2004). 3 Snider, T.H., Wientjes, M.G., Joiner, R.L., Fisher, G.L., “Arsenic distribution in rabbits after Lewisite admini-stration and treatment with British anti-Lewisite (BAL)”, Fundam Appl. Toxicol., 14, 262—272(1990). 4 Patlolla, A.K., Tchounwou, P.B., “Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats”, Mutation Research/Genetic Toxicology and Environ-mental Mutagenesis, 587,126—133(2005). 5 Wu, M.H., Lin, C.J., Chen, C.L., Su, M.J., Sun, S.M., Cheng, A.L., “Direct cardiac effects of As2O3 in rabbits: Evidence of reversible chronic toxicity and tissue accu-mulation of arsenicals after parenteral administration”, Toxicol. Appl. Pharm., 189(3), 214—220(2003). 6 Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.Y., Chen, Z., “Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) (Ⅱ) Clinical efficacy and pharmacokinetics in relapsed pa-tient”, Blood, 89, 3354—3360(1997). 7 Pott, W.A., Benjamin, S.A., Yang, R.S., “Pharmacoki-netics, metabolism, and carcinogenicity of arsenic”, Rev. Environ. Contam. Toxicol., 169, 165—214(2001). 8 Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., Rudzinski, W.E., “Biodegradable polymeric nanoparti-cles as drug delivery devices”, J. Control. Release, 70(1/2), 1—20( 2001). 9 Pan, J.Z., Zhang, L.J, Qian, Y., “Structure-property rela-tionships and models of controlled drug delivery of bio-degradable poly (D, L-lactic acid) microspheres”, Chin. J. Chem. Eng., 12(6), 869—876(2004). 10 Gref, R., Luck, M., Quellec, P., Marchand, M., Del-lacherie, E., Harnisch, S., Blunk, T., Muller, R.H., “‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption”, Colloid. Surf. B: Biointerf., 18(3/4), 301—313(2000). 11 Peracchia, M.T., Gref, R., Minamitake, Y., Domb, A., Lotan, N., Langer, R., “PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Inves-tigation of their drug encapsulation and release charac-teristics”, J. Control. Release, 46(3), 223—231(1997). 12 Achim, G., Peter, S.P., Lucke, A., Lu, L., Mikos, A.G., “Modulation of marrow stromal cell function using poly (D, L-lactic acid)—poly (ethylene glycol)-monomethyl ether surfaces”, J. Biomed. Mat. Res., 46(3), 390—398(1999). 13 Yang, A.S., Liu, W., Yang, L., Li, Z.Y., Xu, H.B., Yang, X.L., “Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vi-tro evaluation”, Int. J. Pharm., 331(1), 123—132(2007). 14 Vonarbourg, A., Passirani, C., Saulnier,p, Benoit, J.P., “Parameters influencing the stealthiness of colloidal drug delivery systems”, Biomaterials, 27, 4356—4373(2006). 15 Avgoustakis, K., Beletsi, A., Panagia, Z., Klepetsanisa, P., Karydasb, A.G., Ithakissios, D.S., “PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degrada-tion, in vitro drug release and in vivo drug residence in blood properties”, J. Control. Release, 79, 123—135(2002). 16 Li, Y.P., Pei, Y.Y., Zhang, X.Y., Gu, Z.H., Zhou, Z.H., Yuan, W.F., Zhou, J.J., Zhu, J.H., Gao, X.J., “PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats”, J. Control. Re-lease, 71(2), 203—211(2001). 17 An, J., Chen, Z., The Handbook of Inorganic Compound. Synthesize, Chemical Industry Press, Beijing (1997). 18 Murakami, H., Kobayashi, M., Takeuchi, H., Kawashima, Y., “Further application of a modified spontaneous emul-sification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparti-cles”, Powder Technol., 107(1/2), 137—143(2000). 19 Feng, S.S., Huang, G., “Effects of emulsifiers on the con-trolled release of paclitaxel [Taxol(R)] from nanospheres of biodegradable polymers”, J. Control. Release, 71(1), 53—69(2001). 20 Hans, M.L., Lowman, A.M., “Biodegradable nanoparti-cles for drug delivery and targeting”, Curr. Opin. Solid State Mat Sci., 6(4), 319—327(2002). 21 Zambaux, M.F., Bonneaux, F., Gref, R., Maincent, P., Dellacherie, E., Alonso, M.J., Labrude, P., Vigneron, C., “Influence of experimental parameters on the character-istics of poly (lactic acid) nanoparticles prepared by a double emulsion method”, J. Control. Release, 50(1—3), 31—40(1998). 22 Douglas, S.J., Illum, L., Davis, S.S., “Particle size and size distribution of poly (butyl 2-cyanoacrylate) nanopar-ticles (II) Influence of stabilizers”, J. Colloid. Interface Sci., 103(1), 154—163(1985). 23 Fresta, M., Cavallaro, G., Giammona, G., Wehrli, E., Puglisi, G., “Preparation and characterization of poly-ethyl-2-cyanoacrylate nanocapsules containing antiepi-leptic drugs”, Biomaterials, 17(8), 751—758(1996). 24 Fuente, H.D., Portales-Pérez, D., Baranda, L., Díaz- Barriga, F., Saavedra-Alanís, V., Layseca, E., Gon-zález-Amaro, R., “Effect of arsenic, cadmium and lead on the induction of apoptosis of normal human mononu-clear cells”, Clin. Exp. Immunol., 129, 8—14(2002). 25 Scholer, N., Olbrich, C., Tabatt, K., Muller, R.H., Hahn, H., Liesenfeld, O., “Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cyto-kine production of macrophages”, Int. J. Pharm., 221(1/2), 57—67(2001). 26 Gref, R., Babak, V., Bouillot, P., Lukina, I., Bodorev, M., Dellacherie, E., “Interfacial and emulsion stabilizing properties of amphiphilic water-soluble poly (ethylene glycol)-poly (lactic acid) copolymers for the fabrication of biocompatible nanoparticles”, Colloid. Surf. A: Phys-icochem. Eng. Aspects, 143(2/3), 413—420(1998).
|